Business Standard

Shortage of key chemical hits Bharat Biotech's Covaxin ramp-up plans

Bharat Biotech is trying to ramp up capacities of Covaxin to 12 million doses per month by July, from the current 5 million doses per month

Lab test, research, r&d, chemicals, medical research, vaccine, health, pharma
Premium

Bharat Biotech is using Kansas-based ViroVax’s adjuvant to boost the immune response to its Covaxin

Sohini Das Mumbai
With Hyderabad-based vaccine maker Bharat Biotech in the midst of ramping up its capacity for Covaxin, sources said the biotechnology company is facing challenges in procuring the adjuvant used in the vaccine.

The unsung hero of vaccines is a component called the adjuvant. It puts a ‘red flag’ on the antigenic component of the vaccine — an inactivated whole or part of a virus or bacteria — and instructs the immune system to mount a defence against that antigen whenever it is encountered.

“One of the reasons for the sluggish pace of the Covaxin production scale-up is the firm facing

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in